Biotechnology - Neurological

Filter

Current filters:

Neurological

Popular Filters

1 to 25 of 185 results

Novartis venture fund leads $34 million financing for Annexon Bioscience

Novartis venture fund leads $34 million financing for Annexon Bioscience

17-12-2014

USA-based Annexon Bioscience says it has closed a $34 million Series A-1 to support the development of…

Annexon BioscienceANX005BiotechnologyFinancialNeurologicalNovartis

Credit Suisse sees PTC Therapeutics as a top stock pick

05-12-2014

Credit Suisse has released a biotech research report from analysts Jason Kantor and Jeremiah Shepard…

BiotechnologyFinancialNeurologicalPTC TherapeuticsRare diseasesRegulationTranslarna

Forward Pharma sues Biogen Idec over Tecfidera sales in Germany

18-11-2014

Danish biopharmaceutical company Forward Pharma has filed a law suit against US biotech major Biogen…

Biogen IdecBiotechnologyForward PharmaGermanyLegalMarkets & MarketingNeurologicalTecfidera

FDA at last approves Genzyme’s Lemtrada

FDA at last approves Genzyme’s Lemtrada

15-11-2014

The US Food and Drug Administration on Friday approved French pharma major Sanofi subsidiary Genzyme’s…

BayerBiotechnologyGenzymeLemtradaNeurologicalRegulationSanofiUSA

Actinogen acquires Edinburgh BioQuarter spin-out Corticrine

Actinogen acquires Edinburgh BioQuarter spin-out Corticrine

31-10-2014

Australian biotech firm Actinogen has acquired Edinburgh BioQuarter spin-out, Corticrine.

ActinogenBiotechnologyCorticrineEdinburgh BioQuarterMergers & AcquisitionsNeurological

Ferrer buys $8 million of Alexza shares, to eliminate certain Adasuve milestone payments

Ferrer buys $8 million of Alexza shares, to eliminate certain Adasuve milestone payments

28-10-2014

US drugmaker Alexza Pharmaceuticals and privately-held Spanish firm Grupo Ferrer Internacional have amended…

AdasuveAlexza PharmaceuticalBiotechnologyFerrer InternacionalFinancialLicensingNeurologicalUSA

Biogen Idec third-qtr net rockets 76% but shares slump

Biogen Idec third-qtr net rockets 76% but shares slump

23-10-2014

US biotech firm Biogen Idec saw its share price plunge 7% to $303.51, after its posted third-quarter…

Biogen IdecBiotechnologyFinancialNeurologicalTecfideraUSA

Astellas and CoMentis to end Alzheimer’s collaboration

20-10-2014

Japanese drug major Astellas Pharma and US biotech firm CoMentis have said they will end their worldwide…

Astellas PharmaBiotechnologyCoMentisLicensingNeurologicalResearch

After nine years, AstraZeneca finally ditches Targacept

12-10-2014

On October 8, 2014, Anglo-Swedish pharma major AstraZeneca finally terminated its collaborative research…

AstraZenecaBiotechnologyGenito-urinaryLicensingNeurologicalTargacept

US FDA grants Fast Track status to BrainStorm Cell Therapeutics for ALS treatment NurOwn

US FDA grants Fast Track status to BrainStorm Cell Therapeutics for ALS treatment NurOwn

07-10-2014

The US Food and Drug Administration has designated a product from stem cell treatment developer BrainStorm…

BiotechnologyBrainStorm Cell TherapeuticsNeurologicalNurOwnRegulationUSA

Acorda Therapeutics to acquire Civitas for $525 million

24-09-2014

US biotech firm Acorda Therapeutics has entered into an agreement to acquire Civitas Therapeutics, a…

Acorda TherapeuticsBiotechnologyCivitas TherapeuticsCVT-301Mergers & AcquisitionsNeurological

Biotie receives final European milestone from Lundbeck on Selincro French launch

Biotie receives final European milestone from Lundbeck on Selincro French launch

19-09-2014

Danish CNS drug specialist Lundbeck has brought Selincro (nalmefene) on the market in France. Selincro,…

BiotechnologyBiotie TherapiesFinlandFranceLicensingLundbeckNeurologicalSelincro

Biogen Idec's Plegridy achieves positive results over two years in multiple sclerosis

Biogen Idec's Plegridy achieves positive results over two years in multiple sclerosis

12-09-2014

US biotech firm Biogen Idec has reported data confirming its Plegridy gives provides treatment effects…

Biogen IdecBiotechnologyNeurologicalPlegridyResearchUSA

Strong and sustained efficacy reported for Tecfidera over five years

Strong and sustained efficacy reported for Tecfidera over five years

12-09-2014

Results from a five-year study with US biotech firm Biogen Idec’s Tecfidera show strong and sustained…

Biogen IdecBiotechnologyNeurologicalResearchTecfideraUSA

XenoPort to collaborate with the NIAAA for Horizant trial

XenoPort to collaborate with the NIAAA for Horizant trial

10-09-2014

Neurological biopharma specialist XenoPort is to enter into an agreement with the National Institute…

Alcohol abuseBiotechnologyHorizantNational Institute on Alcohol Abuse and AlcoholismNeurologicalResearchUKXenoPort

Eisai divests US Zonegran rights to Concordia

Eisai divests US Zonegran rights to Concordia

07-09-2014

Japanese drugmaker Eisai (TYO: 4523) says its US subsidiary has entered into an agreement to divest its…

BiotechnologyConcordia PharmaceuticalsEisaiMergers & AcquisitionsNeurologicalUSAZonegran

AbbVie links with Calico in up to $1.5 billion effort on drug discovery

AbbVie links with Calico in up to $1.5 billion effort on drug discovery

04-09-2014

US pharma company AbbVie has entered a novel R&D collaboration with recently-formed Calico, intended…

AbbVieBiotechnologycalicoNeurologicalOncologyResearch

FDA Breakthrough designation for ACADIA’s Nuplazid for Parkinson’s disease psychosis

FDA Breakthrough designation for ACADIA’s Nuplazid for Parkinson’s disease psychosis

03-09-2014

US biotech firm ACADIA Pharmaceuticals says that the US Food and Drug Administration has granted Breakthrough…

ACADIA PharmaceuticalsBiotechnologyNeurologicalNuplazidpimavanserinRegulationUSA

Alkermes files NDA for aripiprazole lauroxil in schizophrenia

Alkermes files NDA for aripiprazole lauroxil in schizophrenia

26-08-2014

Ireland-headquartered biotech firm Alkermes has submitted a New Drug Application to the US Food and Drug…

AbilifyAlkermesaripiprazole lauroxilBiotechnologyNeurologicalRegulationUSA

Biogen Idec’s Plegridy gains US approval for multiple sclerosis

Biogen Idec’s Plegridy gains US approval for multiple sclerosis

17-08-2014

The US Food and Drug Administration has approved US biotech firm Biogen Idec’s (Nasdaq: BIIB) Plegridy…

Biogen IdecBiotechnologyNeurologicalPlegridyRegulationUSA

IQWiG finds no added benefit for Biogen Idec’s Tecfidera

IQWiG finds no added benefit for Biogen Idec’s Tecfidera

08-08-2014

In its early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG)…

Biogen IdecBiotechnologyGermanyMSNeurologicalPricingRegulationTecfidera

Regulus shares up on deal with Biogen for microRNA biomarkers in MS

Regulus shares up on deal with Biogen for microRNA biomarkers in MS

05-08-2014

Regulus Therapeutics has entered into a new collaboration agreement with fellow US biotech firm Biogen…

Biogen IdecBiotechnologyMultiple sclerosisNeurologicalRegulus TherapeuticsResearchUSA

Charles Ramat and Paul Freiman named co-chief executive of Neurotrope

Charles Ramat and Paul Freiman named co-chief executive of Neurotrope

21-07-2014

US-based Neurotrope, developers of diagnostic and therapeutic technologies for the treatment of neurodegenerative…

BiotechnologyBoardroomBusiness FinanceCo-chiefDiagnostic and therapeutic technologiesNeurologicalNeurotropePermanent chief executiveSyntexUSA

1 to 25 of 185 results

Back to top